J.P. Morgan Keeps Their Buy Rating on Merck & Company (MRK)
In a report released today, Chris Schott from J.P. Morgan maintained a Buy rating on Merck & Company (MRK – Research Report), with a price ...
J.P. Morgan Reaffirms Their Buy Rating on Merck KGaA (0O14)
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target ...
Detroit News24d
Merck sees 2025 launch for simpler version of cancer drug Keytruda
The latest version of Keytruda could eventually capture between 30% and 40% of the market for the original, Merck CEO Rob Davis said at the JPMorgan Healthcare Conference in San Francisco on Monday.
Barron's21d
Almost Every Dow Stock Is Rallying. The Three That Aren’t Have One Thing in Common.
Of the three stocks in the index that were trading lower in Friday morning, all of them feature an ampersand: JPMorgan Chase & Co, Johnson & Johnson, and Merck & Co. The only other Dow stock that ...
Seeking Alpha24d
Merck eyeing 2025 launch for easier-to-use Keytruda
Merck (NYSE:MRK) is preparing to launch a subcutaneously ... in 2025," said MRK CEO Robert Davis on Monday at the JPMorgan Healthcare Conference in San Francisco. "That's actually new information ...